Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
Dear Editor
Mucosal leishmaniasis (ML) is a disease that can destroy cartilages, the pharynx and larynx, as well as bone structures of the face 1 . The treatment of ML is essentially based on the use of antimonial pentavalent. However, this drug has several adverse effects (AEs) and contraindications. Amphotericin B has been an alternative to antimonial pentavalent, mainly the liposomal formulation (L-AMB) 2 . However, the cost of the drug can be prohibitive to developing countries, and the ideal dose has not yet been established. Amphotericin B lipid complex (ABLC) is another lipid formulation of amphotericin B, with less nephrotoxicity than the deoxycholate formulation and is less expensive than L-AMB. As far as we know, this is the first report on a series of cases on the treatment of ML with ABLC. We report 13 cases of patients with ML treated with ABLC from a Brazilian cohort from January 2000 to July 2015.
Patients with confirmed ML older than 18 years and followed-up for at least 6 months were included in the cohort. Patients without confirmation of ML and refusal of treatment were excluded. The diagnosis of ML included the amplification of Leishmania spp. DNA in tissue samples by molecular techniques, isolation of parasites in cultures, or the finding of typical structures during the histological examination or in immunohistochemistry tests. Otorhinolaryngological evaluations were performed in all patients. Pentavalent antimonial was the first option of treatment. Lipid formulations were indicated after pentavalent antimonial failure, appearance of side effects or the presence of a contraindication for the pentavalent antimonial use. The choice of the lipid formulation of amphotericin B was a medical decision and in 13 cases ABLC (1-4 mg/kg/day to achieve a cumulative dose of 1,500 to 2,500 mg) was administered.
Cure, failure and recurrence episodes were previously defined 3 . AEs associated with the treatment of ML were analyzed during the hospitalization period. Acute kidney injury (AKI) was defined according to the AKIN criteria 4 . The median age of the patients was 58 years old and 53.8% of patients were men. Most patients presented symptoms for more than 5 years (65.4%). All species identified were L. braziliensis. Treatment of all patients with ML was performed in the hospital with a median hospitalization time of 25 days. ABLC was associated with several infusion-related AEs ( Table 1 ). The cure rate of the group that used ABLC was 46.1%, and 1 case considered previously cured has recurred. The dosage of ABLC varied from 1 to 4.5 mg/kg (average 2.6 mg/kg). The mean cumulative dose was 1,253 mg (planned cumulative dose of 1,500 to 2,500 mg).
Data on ABLC in the treatment of ML have not been published in the literature, although this drug has been used since the 1990s for the treatment of visceral leishmaniasis 5 . The results showed a success rate limited to 46.1% (6/13) and a relapse rate of 7.7%. Other drugs have shown clinical cure rates between 71.0% and 77.0% of the cases 1 . Recurrence with the use of antimonial pentavalent is around 22%
1 . However, the daily recommended dose was low, not achieving the adequate cumulative dose. The treatment of ML is still far from the ideal because the best performing drugs for this condition have numerous AEs, and drugs that are safer to use have lower efficacy. ABLC presented a low rate of cure and several side effects, suggesting that the use of this drug is questionable. 
